Sangamo BioSciences has received a $6.4m strategic partnership grant from the California Institute for Regenerative Medicine (CIRM) for the development of ZFP Therapeutic for Beta-thalassemia. The application of its zinc finger nuclease ...
Tags: Sangamo, ZFG Therapeutic
bluebird bio has received $9.3m Strategic Partnership Award from California Institute for Regenerative Medicine (CIRM) to support phase 1/2 studies of LentiGlobin to treat beta-thalassemia. bluebird bio chief medical officer David ...
Tags: bluebird bio, LentiGlobin, CIRM
ViaCyte has received a $10.1m strategic partnership award from the California Institute for Regenerative Medicine (CIRM) to develop VC-01, which is a regenerative medicine, consisting of pancreatic beta cell progenitors in a durable ...
Tags: ViaCyte, Diabetes Therapy Development, CIRM